First Clinical Medical College, Shanxi Medical University, Taiyuan, China.
Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.
J Diabetes Investig. 2024 May;15(5):608-613. doi: 10.1111/jdi.14162. Epub 2024 Feb 16.
AIMS/INTRODUCTION: Serum asprosin is expected to become a screening indicator in early-stage diabetic heart disease. The relationship between serum asprosin and left ventricular diastolic dysfunction (LVDD) was studied in elderly patients with type 2 diabetes mellitus in the community.
A total of 252 elderly patients with type 2 diabetes mellitus were recruited from Zhuoma Community Care Station and Chengbei West Street Community Care Service Center in Changzhi City of Shanxi Province from November 2019 to July 2021. Patients were divided into the LVDD group (n = 195) and the non-LVDD group (n = 57). The t-test, Mann-Whitney U test, and χ test were used to compare indicators between the LVDD group and the non-LVDD group. Pearson or Spearman correlation analysis was adopted to evaluate the correlation between serum asprosin and other clinical data. Multivariate logistic regression analysis was applied to analyze the influencing factors on LVDD.
Compared with patients without LVDD, patients with LVDD had a higher level of low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), and asprosin, but a lower level of early diastolic movement speed (A) to diastolic movement velocity (E) (E/A). Asprosin was positively associated with waist circumference (WC), body mass index (BMI), creatinine, triglycerides (P < 0.05), and negatively associated with E/A and high density lipoprotein cholesterol HDL-C (P < 0.05). The risk of LVDD increased with elevated asprosin levels after adjustment for age, systolic blood pressure (SBP), BMI, FPG, and LDL-C. Compared with patients in the lowest tertile of serum asprosin (<275.25 pg/mL), a serum level of asprosin between 275.25-355.08 pg/mL [OR (95% CI) is 2.368 (1.169-4.796), P < 0.05] and asprosin >355.08 pg/mL [OR (95% CI) is 2.549 (1.275-5.095), P < 0.05] patients have a higher risk of left ventricular diastolic dysfunction.
Serum asprosin was positively associated with left ventricular diastolic dysfunction, and the risk of LVDD increased significantly with increased serum levels of asprosin.
目的/引言:血清天冬酰胺酶有望成为早期糖尿病性心脏病的筛查指标。本研究旨在探讨社区 2 型糖尿病老年患者血清天冬酰胺酶与左心室舒张功能障碍(LVDD)的关系。
2019 年 11 月至 2021 年 7 月,选取山西省长治市卓玛社区卫生服务站和城北西街社区卫生服务中心的 252 例 2 型糖尿病老年患者。根据是否存在 LVDD 将患者分为 LVDD 组(n=195)和非 LVDD 组(n=57)。采用 t 检验、Mann-Whitney U 检验和χ检验比较 LVDD 组和非 LVDD 组之间的指标。采用 Pearson 或 Spearman 相关分析评估血清天冬酰胺酶与其他临床数据的相关性。采用多元逻辑回归分析分析 LVDD 的影响因素。
与无 LVDD 的患者相比,LVDD 患者的低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)和天冬酰胺酶水平较高,而舒张早期运动速度(A)与舒张期运动速度(E)比值(E/A)较低。天冬酰胺酶与腰围(WC)、体重指数(BMI)、肌酐、甘油三酯呈正相关(P<0.05),与 E/A 和高密度脂蛋白胆固醇(HDL-C)呈负相关(P<0.05)。在校正年龄、收缩压(SBP)、BMI、FPG 和 LDL-C 后,天冬酰胺酶水平升高与 LVDD 风险增加相关。与血清天冬酰胺酶最低三分位(<275.25 pg/mL)相比,血清天冬酰胺酶在 275.25-355.08 pg/mL 之间[比值比(95%置信区间)为 2.368(1.169-4.796),P<0.05]和>355.08 pg/mL[比值比(95%置信区间)为 2.549(1.275-5.095),P<0.05]的患者发生左心室舒张功能障碍的风险更高。
血清天冬酰胺酶与左心室舒张功能障碍呈正相关,血清天冬酰胺酶水平升高与 LVDD 风险显著增加相关。